New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.

Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.

Japan’s decision gives quizartinib its first approval globally in specific first-line AML indication, in relatively small but high-need patient population.

Dunn is retiring after an 18-year career that included involvement in some high-profile and controversial drug approval decisions, not the least of which is Biogen’s Alzheimer’s treatment Aduhelm; deputy director Teresa Buracchio takes over the neurology office on an acting basis.